Used in targeted cancer therapies, particularly for ovarian and pancreatic cancers where MUC16 (CA-125) is overexpressed. Binds specifically to MUC16 on tumor cells, enabling delivery of cytotoxic agents when conjugated to drugs, as seen in antibody-drug conjugates. Also employed in diagnostic imaging to detect MUC16-positive tumors. Supports research in immunoassays and flow cytometry for evaluating MUC16 expression levels. Investigated for its role in blocking tumor cell adhesion and signaling pathways involved in cancer progression.